Tresiba (insulin degludec) has potential interactions with alcohol, other medications, and some supplements. These interactions could affect how well the drug works or cause harmful effects.

Tresiba was approved by the FDA in 2015 on the basis of top-line results from DEVOTE and Novo has already applied to get the hypoglycaemia data included on the drug’s US label.

Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced that the company presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 receptor agonist (GLP-1 RA ...

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes ...

Novo Nordisk has announced new data supporting the case for its Tresiba long-lasting insulin, with data showing that patients who experience severe hypoglycaemia are at greater risk of death.

Participants were randomized to receive QW GZR4 injection (Part A: N=42; Part B: N=41) or once-daily IDeg (Tresiba ®) injection (Part A: N=48; Part B: N=48) for 16 weeks of treatment.

Notably, GZR4 injection achieved superior HbA1c reduction in patients with inadequate glycemic control on prior basal insulin therapy compared to once-daily insulin degludec (Tresiba ®).

Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced that the company presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 receptor agonist (GLP-1 RA) ...

Indian drugmakers Biocon, Eris Lifesciences, and Wockhardt are ramping up insulin production to capture a growing global opportunity, as market leader Novo Nordisk scales back its presence in ...

See the latest Novo Nordisk AS ADR stock price (NVO:XNYS), related news, valuation, dividends and more to help you make your investing decisions.